{"id":16389,"date":"2022-02-24T22:05:06","date_gmt":"2022-02-24T22:05:06","guid":{"rendered":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/24\/ai-designed-drug-to-treat-lung-disease-tested-on-humans-the-register\/"},"modified":"2022-02-24T22:05:06","modified_gmt":"2022-02-24T22:05:06","slug":"ai-designed-drug-to-treat-lung-disease-tested-on-humans-the-register","status":"publish","type":"post","link":"https:\/\/mailinvest.blog\/index.php\/2022\/02\/24\/ai-designed-drug-to-treat-lung-disease-tested-on-humans-the-register\/","title":{"rendered":"AI-designed drug to treat lung disease tested on humans \u2022 The Register"},"content":{"rendered":"

<\/a>\n<\/p>\n

\n

The first phase of clinical trials testing an AI-designed drug to treat a chronic lung disease is now underway, according to biotech startup Insilico Medicine.<\/p>\n

Using deep learning to discover new drugs is a relatively development in the pharmaceutical industry, and machine learning algorithms are well-suited to the task. Trained on large amounts of data, they can find patterns in genetic information or chemical databases to come up with novel solutions more quickly that may have been missed by scientists.<\/p>\n

But determining whether a new drug designed by automated software will really be effective or not still requires traditional clinical trials. Now, ISM001-055, an “anti-fibrotic small molecule inhibitor,” to treat idiopathic pulmonary fibrosis (IPF) will be put to the test with 80 healthy volunteers.<\/p>\n

\n